Primary biliary cholangitis (PBC) is a chronic progressive autoimmune disorder characterized by small non-purulent ...

AnaptysBio plans to advance rosnilimab for RA, with a program update expected in the first half of 2026. Read why ANAB stock ...

"Highly pathogenic" cases of bird flu has been confirmed at two places in Lancashire.

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long ...

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in ...

Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated ...

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...

This news was covered by the Medical Dialogues Bureau, which was present at the TCT Conference 2025 held in San Francisco, USA.A stratified treatment, based on comprehensive diagnostic ...

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

The Phase 3 ADAPT SERON study met its primary endpoint (p-value=0.0068), demonstrating that AChR-Ab seronegative gMG patients treated with VYVGART achieved a statistically significant improvement in ...